-
Indirect Comparison of Tarlatamab vs. Chemotherapy (CTx) in Patients With Previously Treated, Platinum-Refractory, or Resistant Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 9, 2025, 16:22 PM -
Improving Data Quality in Oncology Electronic Health Record (EHR)-Derived Databases for Research and Regulatory Decision Making
Sep 9, 2025, 16:22 PM -
Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease
Sep 9, 2025, 16:22 PM -
The Use of Real-World Evidence in Health Technology Assessment and the Application of the NICE RWE Framework: A Review of NICE Technology Appraisals
Sep 9, 2025, 16:22 PM -
Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in Brazil
Sep 9, 2025, 16:22 PM -
Optimizing PICO Scoping in EU HTA: Lessons From a HTA Coordination Group PICO Exercise in Advanced NSCLC to Inform Future Best Practice
Sep 9, 2025, 16:22 PM -
Healthcare Costs in Older Adults: XGBoost, NNA, and Logit
Sep 9, 2025, 16:22 PM -
Understanding Reimbursement and Access Policies for Immunoglobulins and Other Plasma-Derived Medicinal Products Across Europe
Sep 9, 2025, 16:22 PM -
How Are Clinical Trials for Breast Cancer Treatments Currently Being Designed? A Clinical Trial Database Analysis
Sep 9, 2025, 16:22 PM -
Treatment Response in Pediatric Patients With Status Epilepticus: A Retrospective Observational Study From Saudi Arabia
Sep 9, 2025, 16:22 PM -
Preventing Bleeds in Pediatric Patients With Hemophilia A: Which Factor Replacement Therapy Offers the Best Protection and at What Cost?
Sep 9, 2025, 16:22 PM -
From Code to Quality: Identifying Quality Assurance Steps for AI Integration in Qualitative Healthcare Research: A Comparative Study of ChatGPT, Atlas.ti, and Traditional Coding
Sep 9, 2025, 16:22 PM -
Launch Price Dynamics of Targeted Therapies in NSCLC: Dissecting the Cost and Value Across Biomarker Segments
Sep 9, 2025, 16:22 PM -
Do The Guardrails Have Any Effect at All? An Analysis of the Impact of the 2022 FINSTG Guardrails on the German AMNOG Process
Sep 9, 2025, 16:22 PM -
Real-World Findings From the Provent Study of Dupilumab Therapy for Severe Asthma: 2-Year Analysis
Sep 9, 2025, 16:22 PM -
Impact Of Dupilumab Treatment on Work-Related Medical Leave In Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study
Sep 9, 2025, 16:22 PM -
Care of Patients With Phenylketonuria (PKU) in Germany a Claims Data Analysis From 2013 to 2023
Sep 9, 2025, 16:22 PM -
Beyond the QALY: An Analysis of Uncaptured Benefits in NICE Oncology Technology Appraisals 2023-2025
Sep 9, 2025, 16:22 PM -
Balancing Cost-Effectiveness With Societal Values: A Representative Survey of Norwegian Attitudes Toward Healthcare Resource Allocation
Sep 9, 2025, 16:22 PM -
Patient Preferences in Gene Therapy Development for Arrhythmogenic Cardiomyopathy: The UR-HEART Qualitative Study
Sep 9, 2025, 16:22 PM
